SG11202103001PA - Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application - Google Patents
Hmgb1 protein derivatives for the removal of biofilms cross-reference to related applicationInfo
- Publication number
- SG11202103001PA SG11202103001PA SG11202103001PA SG11202103001PA SG11202103001PA SG 11202103001P A SG11202103001P A SG 11202103001PA SG 11202103001P A SG11202103001P A SG 11202103001PA SG 11202103001P A SG11202103001P A SG 11202103001PA SG 11202103001P A SG11202103001P A SG 11202103001PA
- Authority
- SG
- Singapore
- Prior art keywords
- removal
- related application
- protein derivatives
- hmgb1 protein
- biofilms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862742102P | 2018-10-05 | 2018-10-05 | |
PCT/US2019/054851 WO2020072993A1 (en) | 2018-10-05 | 2019-10-04 | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103001PA true SG11202103001PA (en) | 2021-04-29 |
Family
ID=70054912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103001PA SG11202103001PA (en) | 2018-10-05 | 2019-10-04 | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210340198A1 (en) |
EP (1) | EP3860718A4 (en) |
JP (1) | JP2022504139A (en) |
KR (1) | KR20210070331A (en) |
CN (1) | CN112823038A (en) |
AU (1) | AU2019354829A1 (en) |
BR (1) | BR112021006321A2 (en) |
CA (1) | CA3114905A1 (en) |
IL (1) | IL281720A (en) |
MX (1) | MX2021003838A (en) |
SG (1) | SG11202103001PA (en) |
WO (1) | WO2020072993A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018236271B2 (en) | 2017-03-15 | 2023-12-21 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003295653B2 (en) * | 2002-11-20 | 2007-08-16 | The Feinstein Institute Of Medical Research | Use of HMGB polypeptides for increasing immune responses |
EP1569684A4 (en) * | 2002-11-20 | 2006-08-02 | Critical Therapeutics Inc | Use of hmgb fragments as anti-inflammatory agents |
CN103097399A (en) * | 2010-03-29 | 2013-05-08 | 南加利福尼亚大学 | Compositions and methods for the removal of biofilms |
WO2014016417A1 (en) * | 2012-07-26 | 2014-01-30 | Ospedale San Raffaele Srl | Hmgb1 variants and uses thereof |
US20160194384A1 (en) * | 2014-06-12 | 2016-07-07 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
AU2018236271B2 (en) * | 2017-03-15 | 2023-12-21 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
-
2019
- 2019-10-04 JP JP2021518182A patent/JP2022504139A/en active Pending
- 2019-10-04 MX MX2021003838A patent/MX2021003838A/en unknown
- 2019-10-04 KR KR1020217012845A patent/KR20210070331A/en active Search and Examination
- 2019-10-04 WO PCT/US2019/054851 patent/WO2020072993A1/en active Application Filing
- 2019-10-04 EP EP19868798.0A patent/EP3860718A4/en active Pending
- 2019-10-04 CN CN201980063976.4A patent/CN112823038A/en active Pending
- 2019-10-04 US US17/282,354 patent/US20210340198A1/en active Pending
- 2019-10-04 AU AU2019354829A patent/AU2019354829A1/en active Pending
- 2019-10-04 SG SG11202103001PA patent/SG11202103001PA/en unknown
- 2019-10-04 BR BR112021006321A patent/BR112021006321A2/en not_active IP Right Cessation
- 2019-10-04 CA CA3114905A patent/CA3114905A1/en active Pending
-
2021
- 2021-03-22 IL IL281720A patent/IL281720A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020072993A1 (en) | 2020-04-09 |
EP3860718A4 (en) | 2022-08-31 |
JP2022504139A (en) | 2022-01-13 |
EP3860718A1 (en) | 2021-08-11 |
US20210340198A1 (en) | 2021-11-04 |
KR20210070331A (en) | 2021-06-14 |
CA3114905A1 (en) | 2020-04-09 |
IL281720A (en) | 2021-05-31 |
AU2019354829A1 (en) | 2021-04-29 |
MX2021003838A (en) | 2021-05-27 |
BR112021006321A2 (en) | 2021-07-06 |
CN112823038A (en) | 2021-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3929197C0 (en) | Intermediates for the synthesis of microbiocidal heterobicyclic derivatives | |
IL286592A (en) | Amino acid compositions for the treatment of liver disease | |
IL279592A (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
IL276592A (en) | Derivatives of sobetirome | |
GB2575261B (en) | Intermediates in the synthesis of C3-substituted cephalosporins | |
IL276483A (en) | Continuous process for the preparation of trazodone | |
ZA202000498B (en) | Purification of tobacco-derived protein compositions | |
IL291221A (en) | Processes for the synthesis of valbenazine | |
IL283959A (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
ZA202004466B (en) | Processes for the synthesis of sulfentrazone | |
SG11202103001PA (en) | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application | |
IL283963A (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
IL279410A (en) | Process for the preparation of quinmerac | |
IT201900025186A1 (en) | Method for the purification of cysteamine | |
PT3759082T (en) | Process for the synthesis of 6-chloromethyluracil | |
GB201804905D0 (en) | Cataltic synthesis of biarylic compounds | |
IS2977B (en) | Process for the preparation of intermediates useful in the synthesis of eluxadoline | |
GB201820685D0 (en) | Synthesis of 8-chloroadenosine derivatives | |
PL3713939T3 (en) | Improved process for the synthesis of linker-drug vc-seco | |
GB201807468D0 (en) | Methods of synthesis | |
UA40769S (en) | DESIGN FOR THE FRONT PART OF THE MULTI-COOKER | |
GB201809404D0 (en) | Method of synthesis | |
IT201600129605A1 (en) | COMPOSITION FOR THE TREATMENT OF MUSCLE-SKELETAL PATHOLOGIES | |
IT201700054488A1 (en) | COMPOSITION FOR THE TREATMENT OF SKIN INFLAMMATORY FORMS | |
SI3320102T1 (en) | Method for the synthesis of pentostatin |